PD-1 Blockbusters Face Off in Japan: OPDIVO vs. KEYTRUDA

added blog Health

2025-08-04 09:29:33

Before 2022, OPDIVO, co-created by Ono Pharmaceutical and Bristol Myers Squibb, confronted significant market headwinds within Japan's dynamic oncology sector. The immunotherapy agent witnessed considerable market erosion as KEYTRUDA vs OPDIVO competitive dynamics intensified, with medical professionals increasingly selecting Merck's therapeutic option across multiple clinical scenarios. This...

0 Comments 0 Shares 60 Views 0 Reviews